2,2,6,6-四甲基-四氢硫代吡喃-4-酮 | 22842-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 中文名称: 2,2,6,6-四甲基-四氢硫代吡喃-4-酮
• 英文名称: 2,2,6,6-tetramethyltetrahydro-4H-thiopyran-4-one
• 英文别名: 2,2,6,6-tetramethylthiapyran-4-one；2,2,6,6-tetramethyl-4-thianone；2,2,6,6-tetramethylthian-4-one；2,2,6,6-tetramethyl-tetrahydro-thiopyran-4-one；2,2,6,6-Tetramethyl-tetrahydro-thiopyran-4-on；1-thia-2,2,5,5-tetramethyl-4-cyclohexanone；Tetrahydro-2,2,6,6-tetramethyl-4H-thiopyran-4-one
• CAS: 22842-41-7
• 化学式: C₉H₁₆OS
• 分子量: 172.291
• InChiKey: CGAPIUWHWGPGJN-UHFFFAOYSA-N

物化性质

• 沸点：
  229.39°C (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2,6,6-四甲基-四氢硫代吡喃-4-酮 在 lithium aluminium tetrahydride 、 copper(I) bromide dimethylsulfide complex 、 ammonium acetate 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醚 、 乙二醇 、 甲苯 为溶剂， 反应 3.5h， 生成 2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethylamine
  参考文献：
  名称：

  Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)

  摘要：

  A series of tetrahydropyranyl (THP) derivatives has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents. Structural modification of the submicromolar hit compound 3 led to the potent 3-methoxy substituted analogue 27. Further SAR development around the THP ring resulted in an additional 10-fold increase in potency, exemplified by analogue 75 with an IC50 of 1.3 nM. Active and potent compounds demonstrated a dose-dependent increase in Ras cytosolic protein. Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI(50)) values ranging from 0.3 to >100 mu M. However, none of the cellular effects observed using ICMT inhibitors were as pronounced as those resulting from a farnesyltransferase inhibitor.

  DOI：

  10.1021/jm200249a
• 作为产物：
  描述：

  2,6-二甲基-2,5-庚二烯-4-酮 在 氢氧化钾 作用下， 生成 2,2,6,6-四甲基-四氢硫代吡喃-4-酮
  参考文献：
  名称：

  582.噻虫啉系列的合成。第二部分 二氢衍生物

  摘要：

  DOI：

  10.1039/jr9490002749

文献信息

• [EN] SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] PYRAZOLES SUBSTITUÉS SERVANT DE BLOQUEURS DE CANAL CALCIQUE DE TYPE N
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014028803A1

  公开（公告）日：2014-02-20

  The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.

  本发明涉及式(I)化合物，其中X1、X2、X3、X4、R1、R2、R3和Q如本文所述定义，用作N型钙通道阻断剂。
• INHIBITORS OF C-FMS KINASE
  申请人：Illig Carl R.

  公开号：US20090105296A1

  公开（公告）日：2009-04-23

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  该发明涉及以下式I的化合物： 其中Z、X、J、R2和W如规范中所述，以及其溶剂化合物、水合物、互变异构体和药学上可接受的盐，能够抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了治疗自身免疫疾病；以及伴有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、前列腺癌、肺癌、结肠癌、胃癌、毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经源性疼痛；以及骨质疏松症、帕盖特病和其他骨吸收介导发病率的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎、骨关节炎、假体失败、溶骨性肉瘤、骨髓瘤和肿瘤转移至骨骼的方法，其中使用了式I的化合物。
• [EN] SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] PYRAZOLES SUBSTITUÉS COMME BLOQUEURS DE CANAL CALCIQUE DE TYPE N
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014028800A1

  公开（公告）日：2014-02-20

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, ring A, and G are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和疾病的化合物、组合物和方法，包括疼痛。这些化合物由以下的式子（I）表示：其中R1、R2、环A和G在此处定义。
• Reactivities of variously substituted 4-heteracyclohexanones in the formation of oximes
  作者：Kuppusamy Selvaraj、Palaniappan Nanjappan、Kondareddiar Ramalingam、Krishnasamy Ramarajan

  DOI：10.1039/p29830000049

  日期：——

  The rates of oxime formation of 41 heterocyclic ketones have been measured at 5 °C in aqueous alcoholic solution buffered at pH 6.85. The data indicate an overall second-order reaction, first order each in ketone and hydroxylamine. In all cases investigated the reaction appears to be irreversible under the experimental conditions employed. Increased steric retardation is observed as steric crowding

  已在5°C的pH值为6.85的酒精水溶液中测定了41种杂环酮的肟形成速率。数据表明总体为二级反应，一级反应分别为酮和羟胺。在所研究的所有情况下，该反应在所采用的实验条件下似乎都是不可逆的。随着在羰基官能团周围的空间拥挤的增加，观察到增加的空间延迟，这表明发生了确定胺基对羰基基团的速率的攻击。4-哌啶酮，oxan-4-ones，thian-4-ones，相应的1,1-dioxides和selenan-4-ones肟的形成速率有显着差异。
• SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140162997A1

  公开（公告）日：2014-06-12

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R 1 , R 2 , ring A, and G are defined herein.

  本发明涉及一种用于治疗各种疾病、综合症、病况和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下式子I表示：其中R1、R2、环A和G在此定义。